Providers

Disease severity was strongly associated with health-related quality of life, moderately associated with use of disability insurance, and weakly associated with household income for patients with sickle cell disease.

Among patients with multiple sclerosis, there is a 16% greater risk of infection, including for lower respiratory and herpes virus infections, after administration of fingolimod.

FH Healthcare Indicators reveal trends and patterns in the places where patients receive health care.

Two therapeutic regimens used for the treatment of chronic obstructive pulmonary disease (COPD) are rarely being prescribed to patients without a COPD diagnosis, investigators concluded.

An ongoing multicenter study in Japan will evaluate reductions in pulmonary vascular resistance 8 months after initiating the combination therapy in pulmonary arterial hypertension.

The bipartisan bill spells out 5 step therapy exemptions for patients by amending the Employee Retirement Income Security Act of 1974.

The study was originally undertaken to convince MD Anderson’s providers that publishing survey results online would help their reputations.

A panel at the NCCN Virtual Annual Meeting finds that while primary care physicians and oncologists can share information, records may not be well integrated and in easy-to-use formats.

Penn Medicine's Stephen Schuster, MD, offers an overview of an eventful year in CAR T-cell therapy at the NCCN Virtual Annual Meeting.

Pharmacists from the Cleveland Clinic discuss the impact of payer dispensing requirements, known as white bagging and brown bagging, on oncology practices and on patients.

Minimal residual disease (MRD) is being used more frequently in clinical trials and to identify the best treatment course for patients, but unknowns remain about the optimal use of MRD testing.

Despite HHS’ recommendation that everyone with HIV start antiretroviral therapy (ART) soon after their diagnosis, uptick disparities remain and are especially apparent among persons with drug abuse or dependence.

Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension had similar incidence of COVID-19, but the impact on clinical operations at the centers that treat these patients was substantial.

A panel of experts provided consumer insights into value-based insurance design (VBID) and how the COVID-19 pandemic may have changed consumer behaviors in a way that VBID may be able to address as the country emerges from the pandemic.

Responses from a study of in-person focus groups show that not only do patients report adverse effects on quality of life, physical well-being, and mental health but that their caregivers do as well.

Patients discharged from hospitals after recovering from severe COVID-19 were found to have lasting functional impairment and post-traumatic stress symptoms months after, according to a study.

A desire to remove barriers to high-value care and provide services that would improve health and quality of life drove early adopters of value-based insurance design (VBID).

A panel of policy experts, including employees of the previous 2 administrations and a former lobbyist for health plans, discusses achievements of value-based insurance design and how to take the concept to the next level.

Multiple myeloma is not easily diagnosed, and its early symptoms may be confused for another condition.

Researchers analyzed 2 cohorts of patients with chronic obstructive pulmonary disease (COPD) to characterize who is most at risk for developing hypercapnia and who could most benefit from at-home noninvasive inhalation therapy.

Whole-genome sequencing (WGS) is at least as accurate as conventional tests when it comes to genomic profiling in patients with acute myeloid leukemia and myelodysplastic syndromes.

Heart failure has been shown to be a contributing factor in more deaths in rural vs urban counties in which cardiovascular disease was pinpointed as the underlying cause of death.

Idecabtagene vicleucel induced progression-free survival up to 20 months and a complete response in one-third of patients with multiple myeloma who had relapsed multiple times and had received at least 3 previous lines of treatment.

A review of evidence finds that oxygen therapy may be beneficial for all patients with pulmonary arterial hypertension, not just those who develop severe hypoxemia.

Patients with pulmonary arterial hypertension (PAH) who are treated with selexipag within 6 months of their diagnosis had a reduced risk of morbidity/mortality compared with patients who were treated longer than 6 months after diagnosis.